The top cited articles on bioartificial liver in Web of Science

doi:10.3969/j.issn.2095-4344.2013.31.023

Abstract

Abstract:

BACKGROUND: Bioartificial liver could partially replace the major liver functions, including detoxification, synthesis, secretion and biotransformation.
OBJECTIVE: To use bibliometric indexes to track study focuses on bioartificial liver, and to investigate the relationships among geographic origin, impact factors, and highly cited articles indexed in Web of Science.
METHODS: A list of citation classics for bioartificial liver was generated by searching the database of Web of Science-Expanded using the terms “artificial liver support system” or artificial liver or “bioartificial liver”. The top 33 cited research articles which were cited more than 100 times were retrieved.
RESULTS AND CONCLUSIONS: Of 4 144 articles published, the 33 top-cited articles were published between 1992 and 2010. The highest citations paper was published in 2002, with a total of 668 citations, mean cited 55.67 per year. The total citations of 33 articles were 6 094 times, with a mean of 12.64 citations per article. These top-cited papers came from 11 countries, of which 12 articles came from the United States. University of Rostock led the list of classics with five papers. Harvard University and Massachusetts General Hospital ranked the second with four papers each. The 33 top-cited articles were published in 18 journals, predominantly Annals of Surgery and Hepatology, followed by Artificial Organs and Biotechnology and Bioengineering. Our bibliometric analysis provides a historical perspective on the progress of bioartificial liver research. Articles originating from outstanding institutions of the United States and published in high-impact journals are most likely to be cited.

Key words: organ transplantation, organ transplantation academic discussion, artificial organ, artificial liver, bioartificial liver, liver failure, clinical article, bibliometrics, systematic review

CLC Number:

R318

Zhang Fan, Lao Xue-jun, Jiang Jian-wei, Cao Ming-rong. The top cited articles on bioartificial liver in Web of Science [J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.2013.31.023.

Figures/Tables 6

References

[1] Russell PS. Understanding resource use in liver transplantation. JAMA. 1999;281(15):1431-1432.

[2] Allen JW, Hassanein T, Bhatia SN. Advances in bioartifcial liver devices. Hepatology. 2001;34(3):447-455.

[3] Harper AM, Rosendale JD. The UNOS OPTN waiting list and donor registry: 1988-1996. Clin Transpl.1996:69-90.

[4] Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-1751.

[5] Kimoto S, Sugiura M, Sakamoto K, et al. The artificial liver. Arch De Vecchi Anat Patol. 1960;31:229-239. http://www.ncbi.nlm.nih.gov/pubmed/14409107。

[6] Davenport A, Will EJ, Davison AM. Continuous vs. intermittent forms of haemofiltration and/or dialysis in the management of acute renal failure in patients with defective cerebral autoregulation at risk of cerebral oedema. Contrib Nephrol. 1991;93:225-233.

[7] O’Grady JG, Gimson AES, O’Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal haemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology. 1988;94(5 Pt 1):1186-1192.

[8] Riordan SM, Williams R. Extracorporeal support and hepatocyte transplantation in acute liver failure and cirrhosis. Journal of Gastroenterology and Hepatology 1999;14:757-770.

[9] Ding YT, Xu QX, Qiu YD, et al. Molecular adsorbent recycling system in treating patients with acute liver failure: a bridge to liver transplantation. Hepatobiliary Pancreat Dis Int. 2004;3:508-510.

[10] Eguchi S, Kawazoe Y, Sugiyama N, et al. Effects of recombinant human hepatocyte growth factor on the proliferation and function of porcine hepatocytes. ASAIO Journal. 2000;46(1):56-59.

[11] Stockmann HB, Hiemstra CA, Marquet RL, Ijzermans JN. Extracorporeal perfusion for the treatment of acute liver failure.Annals of Surgery 2000;231:460-470.

[12] Moed HF: New developments in the use of citation analysis in research evaluation. Arch Immunol Ther Exp (Warsz). 2009; 57:13-18.

[13] Adam D: The counting house. Nature. 2002;415 (6873): 726-729.

[14] Hennessey K, Afshar K, Macneily AE. The top 100 cited articles in urology. Can Urol Assoc J. 2009;3:293-302.

[15] Rosenberg AL, Tripathi RS, Blum J. The most influential articles in critical care medicine. J Crit Care. 2010;25: 157-170.

[16] Powers MJ, Domansky K, Kaazempur-Mofrad MR, et al. A microfabricated array bioreactor for perfused 3D liver culture. Biotechnol Bioeng. 2002;78(3):257-269.

[17] Wang XH, Li DP, Wang WJ, et al. Crosslinked collagen/chitosan matrix for artificial livers. Biomaterials. 2003;24(19):3213-3220.

[18] Berthiaume F, Moghe PV, Toner M, et al. Effect of extracellular matrix topology on cell structure, function, and physiological responsiveness: hepatocytes cultured in a sandwich configuration. FASEB J. 1996;10(13):1471-1484.

[19] Tilles AW, Baskaran H, Roy P, et al. Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. Biotechnol Bioeng. 2001;73(5):379-389.

[20] Suzuki A, Zheng Y, Kondo R, et al. Flow-cytometric separation and enrichment of hepatic progenitor cells in the developing mouse liver. Hepatology. 2000;32(6):1230-1239.

[21] Powers MJ, Janigian DM, Wack KE, et al. Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng. 2002;8(3):499-513.

[22] Leclerc E, Sakai Y, Fujii T. Microfluidic PDMS (polydimethylsiloxane) bioreactor for large-scale culture of hepatocytes. Biotechnol Prog. 2004;20(3):750-755.

[23] Fukuda J, Khademhosseini A, Yeo Y, et al. Micromolding of photocrosslinkable chitosan hydrogel for spheroid microarray and co-cultures. Biomaterials. 2006;27(30):5259-5267

[24] Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J Clin Invest. 2002;109(10):1291-1302

[25] Nyberg SL, Remmel RP, Mann HJ, et al. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg. 1994;220(1):59-67.

[26] Bhatia SN, Balis UJ, Yarmush ML, et al. Probing heterotypic cell interactions: hepatocyte function in microfabricated co-cultures. J Biomater Sci Polym Ed. 1998;9(11):1137-1160.

[27] Wolf CF, Munkelt BE. Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries. Trans Am Soc Artif Intern Organs. 1975;21:16-27.

[28] Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology. 1993; 17(2): 258-265.

[29] Rozga J, Holzman MD, Ro MS, et al. Development of a hybrid bioartificial liver. Ann Surg. 1993;217(5):502-509; discussion 509-511.

[30] Nyberg SL, Shatford RA, Peshwa MV, et al. Evaluation of a hepatocyte-entrapment hollow fiber bioreactor: a potential bioartificial liver. Biotechnol Bioeng. 1993;41(2):194-203.

[31] Flendrig LM, la Soe JW, Jörning GG, et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally wound nonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol. 1997;26(6): 1379-1392.

[32] Sussman NL, Chong MG, Koussayer T, et al. Reversal of fulminant hepatic failure using an extracorporeal liver assist device. Hepatology. 1992;16(1):60-65.

[33] Soto-Gutiérrez A, Kobayashi N, Rivas-Carrillo JD, et al. Reversal of mouse hepatic failure using an implanted liver-assist device containing ES cell-derived hepatocytes. Nat Biotechnol. 2006;24(11):1412-1419.

[34] Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg. 1997;225(5):484-491; discussion 491-494.

[35] Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology. 1996;24(6):1446-1451.

[36] Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg. 2004;239(5):660-667; discussion 667-670.

[37] Rozga J, Podesta L, LePage E, et al. A bioartificial liver to treat severe acute liver failure. Ann Surg. 1994;219(5): 538-544; discussion 544-546.

[38] Sussman NL, Gislason GT, Conlin CA, et al. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs. 1994;18(5):390-396.

[39] Strom SC, Fisher RA, Thompson MT, et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation. 1997;63(4):559-569.

[40] Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl. 2000;6(3):277-286.

[41] Stange J, Mitzner SR, Risler T, Erley CM, Lauchart W, Goehl H, et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purifcation system for bioartifcial liver support. Artifcial Organs 1999; 23(4):319-330.

[42] Sorkine P, Ben Abraham R, Szold O, et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med. 2001;29(7):1332-1336.

[43] Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl. 2004;10(9): 1109-1119.

[44] Pitkin Z, Mullon C. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs. 1999;23(9):829-833.

[45] Mitzner SR, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol. 2001;12 Suppl 17:S75-82.

[46] Stange J, Hassanein TI, Mehta R, et al. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs. 2002;26(2):103-110.

[47] Stange J, Mitzner S. A carrier-mediated transport of toxins in a hybrid membrane. Safety barrier between a patients blood and a bioartificial liver. Int J Artif Organs. 1996;19(11): 677-691.

[48] Matsumura KN, Guevara GR, Huston H, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery. 1987;101(1):99-103.

[49] Wang XH, Li DP, Wang WJ, et al. Crosslinked collagen/chitosan matrix for artificial livers. Biomaterials. 2003;24(19):3213-3220.